AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03431207 — intervention group
Intervention type: OTHER
Intervention: Standardized video recording for behaviors
Description: A standardized apparatus, scenario, and procedure was applied to record all the behavioral phenotypes with minimized background interference and stimulation.~For each standardized procedure, the guardian sits in the chair, holding the infant facing the stage. Each infant is given a few minutes to adapt to the surroundings and to be calm before recording. No hints or simulations are permitted during the entire process. The recording process lasted for over 5 minutes to ensure that behavioral phenotypes could be completely recorded.
Study NCT02202200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD- 0332991
Description: PD-0332991 Inhibitor of cyclin-dependant kinase (CDK) 8 schedules will be evaluated PD-0332991 PO QD either at 25 mg, 50 mg, 75 mg, 100 mg, 125 mg, 150 mg, 175 mg and 200 mg~All patients will receive vemurafenib as background therapy ,bid at 720mg bid for the first group (during the first 2 cycle then 960 mg bid if good tolerance) and 960mg bid for all other patients
Study NCT01857817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VT-122
Description: The following will be used in the study for VT-122: propranolol 22 mg immediate-release capsules and etodolac 340 mg capsules.
Study NCT01857817 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo capsules will be prepared to match the active drug.
Study NCT03763851 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Radiotherapy
Description: Palliative RadioTherapy to the symptomatic site
Study NCT00993954 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reduction of Radial Head Subluxation
Description: Nurse group will use hyperpronation with extension for first attempt and supination and flexion for second attempt. Physician controls will use either method at their discretion
Study NCT00993954 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Reduction of Radial Head Subluxation
Description: Nurse group will use hyperpronation with extension for first attempt and supination and flexion for second attempt. Physician controls will use either method at their discretion
Study NCT03932825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrous Oxide
Description: An 1-hour session of inhaled nitrous oxide at concentrations of 50%.
Study NCT03932825 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An 1-hour session of mixed oxygen-air gas(inspired oxygen concentration \~50%)
Study NCT00530868 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Letrozole (Femara)
Description: Letrozole 2.5 mg PO a day for 24 weeks
Study NCT00530868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole; Avastin
Description: Letrozole 2.5 mg PO a day and Avastin 15 mg/kg IV every 3 weeks
Study NCT01990534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Brentuximab vedotin IV infusion
Study NCT03132532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Chemotherapy
Study NCT03132532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Chemotherapy
Study NCT03132532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Chemotherapy
Study NCT03132532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Chemotherapy
Study NCT03132532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Chemotherapy
Study NCT03132532 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Beam Radiation Therapy
Description: Undergo PBT
Study NCT03132532 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03132532 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02030756 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: vibrating capsule
Description: patients will receive vibrating capsule for 8 weeks of treatment \[1 every 3 days (+/- 1 day)\].
Study NCT02030756 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham non-vibrating capsule
Description: patients will receive sham non-vibrating capsule for 8 weeks of treatment \[1 every 3 days (+/- 1 day)\].
Study NCT03234062 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 25% Cho diet
Description: Subjects will consume meals containing 25% of the recommended intake of Choline (137.5 mg Choline/day) for 2 weeks. On day 12 of the diet period, subjects will consume 250 mg of Cho in the form of Cho chloride-(trimethyl-d9, 9%, Cambridge Isotope Laboratories, Tewksbury, Massachusetts, (USA), as a bolus.
Study NCT03234062 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 50% Cho diet
Description: Subjects will consume meals containing 50% of the recommended intake of Choline (275 mg Choline/day) for 2 weeks. On day 12 of the diet period, subjects will consume 250 mg of Cho in the form of Cho chloride-(trimethyl-d9, 9%, Cambridge Isotope Laboratories, Tewksbury, Massachusetts, (USA), as a bolus.
Study NCT03234062 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 100% Cho diet
Description: Subjects will consume meals containing 100% of the recommended intake of Choline (550 mg Choline/day) for 2 weeks. On day 12 of the diet period, subjects will consume 250 mg of Cho in the form of Cho chloride-(trimethyl-d9, 9%, Cambridge Isotope Laboratories, Tewksbury, Massachusetts, (USA), as a bolus.
Study NCT02525861 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GLASSIA
Description: Participants will receive weekly IV infusions of GLASSIA at 60 mg/kg BW active A1PI protein administered at a rate of 0.2 mL/kg/min for 25 weeks (25 planned infusions) via an IV administration.
Study NCT04276766 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Crossover intervention
Description: Drink consumption was followed by regular BP measurements and collection of saliva samples every 30 minutes for four hours. Microcirculatory measurements were then repeated and saliva and urine samples were collected again.~After the last measurement subjects were provided with a standardized meal with a very low nitrate intake to eat within 30minutes. Participant then left the research centre and they were asked to collect a saliva sample after two hours from the completion of the meal. This was immediately followed a dose of labelled nitrate (4mg in 100ml of distilled water) to drink within one minute. Subjects were then asked to collect six additional saliva samples until the next morning (four before going to bed and two in the morning), accompanied by measurements of resting BP.~Cross-over assessments were then repeated in the same order at Visit 3, followed a wash-out period of at least one week before entering the second arm of the study.
Study NCT04276766 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Crossover intervention
Description: Drink consumption was followed by regular BP measurements and collection of saliva samples every 30 minutes for four hours. Microcirculatory measurements were then repeated and saliva and urine samples were collected again.~After the last measurement subjects were provided with a standardized meal with a very low nitrate intake to eat within 30minutes. Participant then left the research centre and they were asked to collect a saliva sample after two hours from the completion of the meal. This was immediately followed a dose of labelled nitrate (4mg in 100ml of distilled water) to drink within one minute. Subjects were then asked to collect six additional saliva samples until the next morning (four before going to bed and two in the morning), accompanied by measurements of resting BP.~Cross-over assessments were then repeated in the same order at Visit 3, followed a wash-out period of at least one week before entering the second arm of the study.
Study NCT03042780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX
Description: The FOLFIRINOX regimen consists of oxaliplatin given as a 2-hour intravenous infusion, immediately followed by leucovorin given as a 2-hour intra-venous infusion, with the addition, after 30 minutes, of irinotecan given as a 90-minute intravenous infusion. This study treatment is immediately followed by a continuous intravenous infusion of 5-Fluorouracil (5-FU) over a 46-hour period every 2 weeks.
Study NCT03042780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF)
Description: The use of G-CSF will not be mandatory as primary prophylaxis, but will be allowed at investigators' discretion. If febrile neutropenia occurs, than the use of G-CSF will be mandatory after each following cycle of treatment.
Study NCT02921568 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: P200TE
Description: Optical Coherence Tomography and Scanning Laser Ophthalmoscope device.
Study NCT02921568 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Spectral OCT/SLO
Description: Optical Coherence Tomography and Scanning Laser Ophthalmoscope device.
Study NCT00900523 — intervention group
Intervention type: GENETIC
Intervention: protein expression analysis
Description: protein expression analysis
Study NCT00900523 — intervention group
Intervention type: OTHER
Intervention: immunohistochemistry
Description: immunohistochemical staining of tumor tissue to measure COX-1 and COX-2 levels
Study NCT02193360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FFP104
Description: Cohorts receiving multiple weekly or biweekly i.v. doses of FFP104. FFP104 dose levels: 1.0, 2.5 and 5.0 mg/kg. Subjects will be treated for 12 weeks and then followed for safety and efficacy assessments for an additional 12 weeks.
Study NCT01096888 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced WIC Program
Description: Applying an internet based weight loss intervention to participants in the WIC program to enhance weight loss post partum.
Study NCT02925572 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cycling exercises
Description: All measurements are performed before and after the training program (12 weeks)
Study NCT03531281 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allo-HCT
Study NCT03531281 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allo-HCT
Study NCT03531281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT03531281 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Given IV
Study NCT03531281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study NCT03531281 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Given IV
Study NCT03531281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goat Milk
Description: Given human lysozyme goat milk PO
Study NCT03531281 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03531281 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03531281 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Palifermin
Description: Given IV
Study NCT03531281 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Palifermin
Description: Given IV
Study NCT03531281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Given PO
Study NCT03531281 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus
Description: Given PO
Study NCT03531281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV and PO
Study NCT03531281 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Given IV and PO
Study NCT03531281 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo FTBI
Study NCT03531281 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Total-Body Irradiation
Description: Undergo FTBI
Study NCT02649049 — intervention group
Intervention type: OTHER
Intervention: there is no intervention
Study NCT03186118 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T-cell Antigen Presenting Cells expressing truncated CD19 (T-APC)
Description: Autologous CD4 and CD8 T cells transduced to express a truncated CD19 (CD19t) Transgene
Study NCT00633711 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automatic (variable, automatically controlled) pressure CPAP
Description: CPAP at a variable level according to instantaneous patients' needs for treatment of sleep respiratory disorders, as evaluated by machine's software.~Home nocturnal usage. Two-month treatment.
Study NCT00633711 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: fixed continuous positive airway pressure (CPAP)
Description: CPAP at a constant level, whose efficacy on respiratory disorders has been determined by nocturnal titration.~Home nocturnal usage. Two-month treatment.
Study NCT02294682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2140944
Description: Immediate release capsules (pink hard gelatin size 00 capsule, with no external marking, filled with slightly agglomerated pale yellowish to grayish yellow powder) containing GSK2140944 500 mg and inactive formulation excipients. GSK2140944 will be administered orally once 1500 mg (3 capsules) or 3000 mg (6 capsules).
Study NCT03133806 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasept LAA Closure System
Description: The Ultrasept Left Atrial Appendage Closure System Device is a percutaneous transcatheter device intended to prevent thrombus embolization from the left atrial appendage (LAA) in patients with non-valvular atrial fibrillation.
Study NCT03422172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral CAB
Description: CAB tablet will be formulated as white to almost white, oval shaped, film coated 30 mg tablets, administered orally once daily. The CAB tablets will be packaged in bottles containing 30 tablets each.
Study NCT03422172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAB LA
Description: CAB LA is a sterile white to slightly colored suspension containing 200 mg/mL of CAB as free acid for administration by IM injection in gluteus medius.
Study NCT02595931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berzosertib
Description: Given IV
Study NCT02595931 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy Specimen
Description: Undergo biopsy
Study NCT02595931 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Correlative studies
Study NCT02595931 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT02595931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Given IV
Study NCT03217188 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: conventionally fractionated full dose re-irradiation
Description: re-irradiation \[60-70 Gy (RBE) in 2 Gy (RBE) fractions
Study NCT03217188 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: hypofractionated palliative re-irradiation
Description: course or a hypofractionated palliative re-irradiation Quad Shot course (3.7 Gy (RBE) twice daily x 2 days, followed by a 4 week break \[+/- 2 weeks\], repeated up to 4 cycles).
Study NCT00066742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tirapazamine
Description: Given IV
Study NCT00066742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study NCT00066742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV
Study NCT00066742 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiation therapy
Study NCT00066742 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00832117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone
Description: Escalation: Solution, intravenous (IV), 32-40 mg/m2, every 3 weeks, approximately 6 months
Study NCT00832117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Escalation: Solution, IV, 60-100 mg/m2, every 3 weeks, approximately 6 months
Study NCT00832117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone
Description: Expansion: Solution, IV, 32 mg/m2, every 3 weeks, approximately 6 months
Study NCT00832117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Expansion: Solution, IV, 60-80 mg/m2, every 3 weeks, approximately 6 months
Study NCT04699175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR021618
Description: Treatment group A:HR021618; high dose
Study NCT04699175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR021618
Description: Treatment group B:HR021618; low dose
Study NCT04699175 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment group C: HR021618 blank preparation.
Study NCT01647750 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Levothyroxine
Description: Participants in the lower dose arm of the study will receive a lower dose of levothyroxine than their usual dose
Study NCT01647750 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Levothyroxine
Description: Participants in the standard dose of treatment will receive their usual dose of levothyroxine
Study NCT02321826 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music
Description: Participants choice among 4 genres of music matched on music characteristics
Study NCT02321826 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Audiobook
Description: Participants choice among 4 types of audiobooks
Study NCT00791336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nelfinavir
Description: 1250 mg twice daily starting for approximately 6.5 weeks.
Study NCT00960960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered IV at a dose of 10 mg/kg on Days 1 and 15 of each 28-day cycle.
Study NCT00960960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pictilisib
Description: Pictilisib will be administered PO QD on escalating doses.
Study NCT00960960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole will be administered PO at a dose of 2.5 mg QD for for each 28-day cycle.
Study NCT00960960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be administered IV at a dose of 90 mg/m\^2 on Days 1, 8, and 15 of each 28-day cycle.
Study NCT00960960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab will be administered IV at a dose of 2-4 mg/kg on on Days 1, 8, 15, and 22 of each 28-day cycle.
Study NCT01996813 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thigh-high compression stockings
Description: The intervention in this study are thigh-high compression stockings manufactured by Covidien.
Study NCT01318954 — intervention group
Intervention type: BIOLOGICAL
Intervention: Allergen immunotherapy
Study NCT02852161 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnet assissted capsule endoscopy
Description: Patients due to have a clinically indicated gastroscopy will be asked to have a MACE procedure on the same day
Study NCT02852161 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Magnet assissted capsule endoscopy
Description: Patients due to have a clinically indicated gastroscopy will be asked to have a MACE procedure on the same day
Study NCT02215837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Oxaliplatin 85mg/m2 IV over 2 hours, day 1; Leucovorin 400mg/m2 IV over 2 hours, day 1; 5-FU 400mg/m2 IV bolus on day 1, then 1200mg/m2/day for 2 days IV continuous infusion; Repeat every 2 weeks.
Study NCT02215837 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Chemotherapy
Description: Oxaliplatin 85mg/m2 IV over 2 hours, day 1; Leucovorin 400mg/m2 IV over 2 hours, day 1; 5-FU 400mg/m2 IV bolus on day 1, then 1200mg/m2/day for 2 days IV continuous infusion; Repeat every 2 weeks.
Study NCT02215837 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ag-D-CIK
Description: 8×10\^9 autologous tumor lysate pulsed D-CIK cells for each infusion, IV (in the vein) for 3 cycles, each cycle received four infusions on day 14, 16, 30 and 32.
Study NCT01480453 — intervention group
Intervention type: DEVICE
Intervention: Trabecular Metal Humeral Stem
Description: Trabecular Metal Humeral Stem used in primary, total or hemi shoulder arthroplasty
Study NCT04559828 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Experimental meal
Description: Two dietary oils will be administrated as part of a single experimental meal, for the present is a postprandial phase study.
Study NCT03106181 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iStent inject®
Description: Insertion of iStent inject®